drugset / Trial / NCT00089674

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

NCT00089674

Phase 3 Completed 1468 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Timeline

Start
2004-08-01
Primary completion
2008-05-16
Completion
2010-05-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications